Loading...

Laura Van 'T Veer, PhD

Title(s)Professor, Laboratory Medicine
SchoolSchool of Medicine
Address2340 Sutter Street
San Francisco CA 94115
Phone415-476-6023
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Leiden, Leiden, NetherlandsPhD1989Medicine, Oncogene Activation and Tumorigenesis
    University of Amsterdam, Amsterdam, NetherlandsMSc1984Experimental Oncology
    University of Amsterdam, Amsterdam, Netherlands BSc1980 Biology, Molecular Oncology
    Collapse Awards and Honors
    European Patent Office (EPO) 2015European Inventor Award 2015
    European Union Prize for Women Innovators 2014Second Prize, European Union Prize for Women Innovators
    AACC 2012AACC Outstanding Speaker Award
    Indiana University, School of Medicine2009First Annual Harry and Edith Gladstein Award,
    Breast Cancer Research Fund2007  - 2011Breast Cancer Research Fund (BCRF-Pink Ribbon US) grant award
    European Society Medical Oncology (ESMO) 2007Lifetime Achievement Award for Translational Research in Breast Cancer
    EBCC52006Van der Scheuren award lecture for European Breast Cancer Research
    International Agency for Research on Cancer (IARC) , Lyon, France2005Medal of Honor
    The Irvington Institute for Medical Research, New York, USA1991  - 1994Postdoctoral Fellowship
    NWO The Netherlands Organization for Scientific Research, 's-Gravenhage, The Netherlands1989  - 1990Long-term Fellowship

    Collapse Overview 
    Collapse Overview
    Laura van ‘t Veer, PhD is Professor of Laboratory Medicine is the Program Leader of the UCSF Helen Diller Family Comprehensive Cancer Center Breast Oncology Program (BOP), Director of Applied Genomics with the UCSF Helen Diller Family Comprehensive Cancer Center, and UCSF-Site Principal Investigator of the Athena Breast Health Network.

    Dr. van ‘t Veer is a world renowned Molecular Biologist and inventor of MammaPrint®. A recent publication in the New England Journal of Medicine on the MINDACT trial shows that 46% of breast cancer patients who are clinically high risk and are therefor considered for chemotherapy, can safely forgo this treatment based on a Low Risk MammaPrint result (NEJM 2016, Aug 25).
    Dr. van 't Veer's research focuses on personalized medicine, to advance patient management based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. This allows clinicians to optimally assign systemic therapy for those patients in need of such treatment, and to ensure the selection of the therapy that is most effective. Dr. van ‘t Veer’s research shows that molecular diagnostics and microarray genomics technology increasingly impact patient management. Molecular genomics contributes to the knowledge of who is at risk for breast cancer, how external factors may influence this risk, whether breast tumors are likely to metastasize or not, and which subtype of tumors will likely respond to what therapy. Her current research, involving genomics data from various types, is aimed to understand the molecular basis for early response to therapy as a surrogate for outcome prediction.

    Dr. van ‘t Veer is the Biomarker Committee Chair for the Foundation of NIH sponsored multicenter adaptive clinical trial I-SPY 2, overseeing the processes for FDA-IDE biomarker usage and qualifying biomarker companion diagnostic testing. She served 2010-2014 as Board member of the American Association of Cancer Research. She has over 230 peer-reviewed scientific articles and is co-inventor of 6 patents. Dr. van 't Veer received the 2007 European Society of Medical Oncology (ESMO) life-time achievement award for translational research in breast cancer and the prestigious European Union Women Innovator Award, 2nd prize in 2014.

    Dr. van ‘t Veer received undergraduate training in biology and a master of science in molecular oncology (1984) at the University of Amsterdam in the Netherlands. She earned her PhD in Medicine for a dissertation on oncogene activation and tumorigenesis in 1989 at the University of Leiden. She then completed two postdoctoral fellowships, first at the Cancer Center of Harvard Medical School and Massachusetts General Hospital in Boston (1989-1991), followed by the Division of Molecular Carcinogenesis at The Netherlands Cancer Institute (1992-1993). She then joined The Netherlands Cancer Institute as a Molecular Biologist in the Department of Pathology. At the institute she assumed increasing responsibilities, starting with the initiation and leadership of the Departments of Molecular Pathology and Genetic Counseling, culminating with her appointment as the Head of Diagnostic Oncology, overseeing the clinical work and associated research. In 2003 she was one of the founders of the Netherlands Cancer Institute spin-off, the molecular profiling company Agendia. Concurrent to her employment at The Netherlands Cancer Institute Dr. van ‘t Veer served as the Chief Operating Officer from 2002-2007 and as the Chief Research Officer from 2007-2014 for Agenda NV, a company she founded in Amsterdam to make her scientific discoveries available to clinicians for patient use. MammaPrint® obtained the first FDA 510K ‘In Vitro Diagnostic Multigene Index Assay’ (IVDMIA) clearance in 2007, and is included in several international and national guidelines for breast cancer management.

    After a 2008-2009 appointment as Visiting Associate Professor at the UCSF Helen Diller Family Cancer Center, Dr. van ‘t Veer moved to UCSF as Professor of Laboratory Medicine in 2010 and assumed leadership of the Bay Area Breast Cancer SPORE and the BOP. In 2011 she assumed leadership of the Athena Breast Health Network at UCSF. She holds the Angela and Shu Kai Chan Endowed Chair in Cancer Research. She has established at UCSF a Laboratory for Applied Genomics that is CLIA licensed and provides a robust infrastructure and testing incubator lab for new molecular diagnostics of cancer.

    Collapse Research 
    Collapse Research Activities and Funding
    Center for Big Data in Translational Genomics
    NIH/NHGRI U54HG007990Jun 18, 2016 - Aug 31, 2018
    Role: Co-Principal Investigator
    Integrative signaling models to decipher complex cancer phenotypes
    NIH/NCI U01CA164720Aug 8, 2012 - Jul 31, 2017
    Role: Co-Principal Investigator
    Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes
    NIH/NCI U54CA163123Sep 23, 2011 - Oct 31, 2016
    Role: Co-Principal Investigator
    SPORE in Breast Cancer
    NIH/NCI P50CA058207Aug 1, 1997 - Sep 29, 1995
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The San Francisco Cancer Initiative: A Community Effort To Reduce The Population Burden Of Cancer. Health Aff (Millwood). 2018 01; 37(1):54-61. Hiatt RA, Sibley A, Fejerman L, Glantz S, Nguyen T, Pasick R, Palmer N, Perkins A, Potter MB, Somsouk M, Vargas RA, van 't Veer LJ, Ashworth A. PMID: 29309234.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    2. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. Breast Cancer Res Treat. 2018 01; 167(1):123-131. Viale G, de Snoo FA, Slaets L, Bogaerts J, van 't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Glas A, Russo L, Dell'Orto P, Tryfonidis K, Litière S, Cardoso F. PMID: 28929359.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    3. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. PMID: 28893315.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    4. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Res. 2017 Aug 25; 19(1):99. Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L. PMID: 28851423.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    5. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. Breast Cancer Res Treat. 2017 Nov; 166(2):593-601. van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS. PMID: 28776283.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016 Aug 25; 375(8):717-29. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M. PMID: 27557300.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansCTClinical Trials
    7. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010 Jun; 47(6):421-8. Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van 't Veer LJ. PMID: 20522432.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    8. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010 Apr; 120(3):655-61. Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ. PMID: 20204499.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    9. Radiation-associated breast tumors display a distinct gene expression profile. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):540-7. Broeks A, Braaf LM, Wessels LF, van de Vijver M, De Bruin ML, Stovall M, Russell NS, van Leeuwen FE, Van 't Veer LJ. PMID: 20117289.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    10. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009 Dec 24; 462(7276):1005-10. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Børresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR. PMID: 20033038.
      View in: PubMed   Mentions: 369     Fields:    Translation:HumansCells
    11. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol. 2010 Apr; 21(4):717-22. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJ, van 't Veer LJ. PMID: 19825882.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    12. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer. 2009 Sep; 45 Suppl 1:11-26. Linn SC, Van 't Veer LJ. PMID: 19775601.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    13. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res. 2008; 10(6):R93. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF. PMID: 19014521.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    14. Recent advances in metastasis research. Curr Opin Genet Dev. 2008 Feb; 18(1):35-41. Molloy T, van 't Veer LJ. PMID: 18337081.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    15. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat. 2008 Jan; 107(2):243-8. Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, Van 't Veer LJ. PMID: 17393301.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    16. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007; 9(2):R26. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van Leeuwen FE, Van 't Veer LJ. PMID: 17428320.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    17. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006 Oct; 3(10):540-51. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M. PMID: 17019432.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    18. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 01; 23(31):7804-10. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL. PMID: 16219936.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    19. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005 Aug; 5(8):591-602. Weigelt B, Peterse JL, van 't Veer LJ. PMID: 16056258.
      View in: PubMed   Mentions: 615     Fields:    Translation:Humans
    20. Laura van 't Veer, PhD: bringing tumor gene profiles into the clinic. Interview. JAMA. 2004 Aug 11; 292(6):675. van 't Veer L. PMID: 15304450.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat. 2004 Apr; 84(3):225-33. Voskuil DW, Bosma A, Vrieling A, Rookus MA, van 't Veer LJ. PMID: 15026620.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    22. [Genetic research with stored human tissue: a coding procedure with optimal use of information and protection of privacy]. Ned Tijdschr Geneeskd. 2004 Mar 20; 148(12):564-8. Schmidt MK, van Leeuwen FE, Klaren HM, Tollenaar RA, van 't Veer LJ. PMID: 15074178.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    23. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. PMID: 14981104.
      View in: PubMed   Mentions: 220     Fields:    Translation:Humans
    24. Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? Cancer Res. 2004 Feb 01; 64(3):840-3. Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JG, van den Ouweland AM, Wagner TM, Devilee P, Simard J, van 't Veer LJ, Goldgar DE, Meijers-Heijboer H. PMID: 14871810.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    25. Expression of a novel lacrimal gland gene lacritin in human breast tissues. J Cancer Res Clin Oncol. 2003 Dec; 129(12):735-6. Weigelt B, Bosma AJ, van 't Veer LJ. PMID: 14574570.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    26. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer. 2003 Apr 07; 88(7):1091-4. Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ. PMID: 12671691.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    27. [From gene to disease; ataxia telangiectasia]. Ned Tijdschr Geneeskd. 2003 Mar 01; 147(9):386-9. Broeks A, van 't Veer LJ, Ottenheim C, Hiel JA, Kleijer WJ, Weemaes C. PMID: 12661456.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    28. Expression profiling predicts outcome in breast cancer. Breast Cancer Res. 2003; 5(1):57-8. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Bernards R, Friend SH. PMID: 12559048.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    29. Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res. 2002 Jun; 8(6):1871-7. Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, Hart AA, Rodenhuis S, van 't Veer LJ. PMID: 12060630.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    30. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002 Jan 31; 415(6871):530-6. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. PMID: 11823860.
      View in: PubMed   Mentions: 2451     Fields:    Translation:Humans
    31. The microarray way to tailored cancer treatment. Nat Med. 2002 Jan; 8(1):13-4. Van 't Veer LJ, De Jong D. PMID: 11786894.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    32. Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas. Cancer Res. 2000 Feb 01; 60(3):530-3. van Dijk MA, Hart AA, van 't Veer LJ. PMID: 10676630.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    33. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000 Feb; 66(2):494-500. Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ. PMID: 10677309.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    34. Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am. 2000 Jan-Feb; 6(1):2-10. Bartelink H, Begg AC, Martin JC, van Dijk M, Moonen L, van 't Veer LJ, Van de Vaart P, Verheij M. PMID: 10696731.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer. 1999 Mar; 79(9-10):1475-8. Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van der Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG, Van 't Veer LJ. PMID: 10188893.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    36. [The role of genetic factors in the development of gastric cancer]. Ned Tijdschr Geneeskd. 1999 Feb 13; 143(7):342-6. Taal BG, van Loon HJ, Kahn N, de Jong D, Vasen HF, van 't Veer LJ. PMID: 10221095.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    37. [Epstein-Barr virus in a donor kidney as a cause of non-Hodgkin lymphoma]. Ned Tijdschr Geneeskd. 1999 Feb 13; 143(7):360-4. Kersten MJ, Surachno S, Koopman MG, van 't Veer LJ, Pals ST, van Oers MH. PMID: 10221099.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    38. Towards prediction and modulation of treatment response. Radiother Oncol. 1999 Jan; 50(1):1-11. Bartelink H, Begg A, Martin JC, van Dijk M, van 't Veer L, van der Vaart P, Verheij M. PMID: 10225551.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    39. The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol. 1998 Dec; 9(12):1269-76. Lambrechts AC, van 't Veer LJ, Rodenhuis S. PMID: 9932154.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    40. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure. Cancer Epidemiol Biomarkers Prev. 1998 Jul; 7(7):571-7. Dallinga JW, Pachen DM, Wijnhoven SW, Breedijk A, van 't Veer L, Wigbout G, van Zandwijk N, Maas LM, van Agen E, Kleinjans JC, van Schooten FJ. PMID: 9681524.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    41. Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers. Carcinogenesis. 1998 May; 19(5):819-25. Godschalk RW, Maas LM, Van Zandwijk N, van 't Veer LJ, Breedijk A, Borm PJ, Verhaert J, Kleinjans JC, van Schooten FJ. PMID: 9635869.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    42. Multiple malignancies in a patient with bilateral retinoblastoma. J Laryngol Otol. 1998 Feb; 112(2):189-92. Ceha HM, Balm AJ, de Jong D, van 't Veer LJ. PMID: 9578885.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    43. ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population. Hum Mutat. 1998; 12(5):330-7. Broeks A, de Klein A, Floore AN, Muijtjens M, Kleijer WJ, Jaspers NG, van 't Veer LJ. PMID: 9792409.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    44. The role of prognostic factors and oncogenes in the detection and management of non-small-cell lung cancer. Oncology (Williston Park). 1998 Jan; 12(1 Suppl 2):55-9. Van Zandwijk N, Van 't Veer LJ. PMID: 9516613.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration. Diagn Mol Pathol. 1997 Dec; 6(6):353-60. de Lange MS, Top B, Lambrechts C, Maas RA, Peterse HL, Mooi WJ, van 't Veer LJ, Rodenhuis S. PMID: 9559296.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    46. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997 Nov; 17(3):341-5. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drüsedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van 't Veer LJ, Bakker E, van Ommen GJ, Devilee P. PMID: 9354803.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCells
    47. A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma. Cancer Res. 1997 Aug 15; 57(16):3478-85. van Dijk MA, Floore AN, Kloppenborg KI, van 't Veer LJ. PMID: 9270016.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    48. Oligoclonal peripheral T-cell lymphocytosis as a result of aberrant T-cell development in a cortical thymoma. Diagn Mol Pathol. 1997 Aug; 6(4):244-8. de Jong D, Richel DJ, Schenkeveld C, Boerrigter L, van 't Veer LJ. PMID: 9360846.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    49. The XPB subunit of repair/transcription factor TFIIH directly interacts with SUG1, a subunit of the 26S proteasome and putative transcription factor. Nucleic Acids Res. 1997 Jun 15; 25(12):2274-83. Weeda G, Rossignol M, Fraser RA, Winkler GS, Vermeulen W, van 't Veer LJ, Ma L, Hoeijmakers JH, Egly JM. PMID: 9173976.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    50. Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev. 1997 Jan 15; 11(2):226-40. Alkema MJ, Bronk M, Verhoeven E, Otte A, van 't Veer LJ, Berns A, van Lohuizen M. PMID: 9009205.
      View in: PubMed   Mentions: 81     Fields:    Translation:AnimalsCells
    51. RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein. Oncogene. 1996 Jul 18; 13(2):353-62. Wolthuis RM, Bauer B, van 't Veer LJ, de Vries-Smits AM, Cool RH, Spaargaren M, Wittinghofer A, Burgering BM, Bos JL. PMID: 8710374.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    52. E2F-5, a new E2F family member that interacts with p130 in vivo. Mol Cell Biol. 1995 Jun; 15(6):3082-9. Hijmans EM, Voorhoeve PM, Beijersbergen RL, van 't Veer LJ, Bernards R. PMID: 7760804.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsCells
    53. Activation of the mas oncogene involves coupling to human alphoid sequences. Oncogene. 1993 Oct; 8(10):2673-81. van 't Veer LJ, van der Feltz MJ, van den Berg-Bakker CA, Cheng NC, Hermens RP, van Oorschot DA, Kievits T, Schrier PI. PMID: 8378079.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    54. TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. Proc Natl Acad Sci U S A. 1993 Sep 15; 90(18):8489-93. Hateboer G, Timmers HT, Rustgi AK, Billaud M, van 't Veer LJ, Bernards R. PMID: 7690963.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    55. N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B. EMBO J. 1993 Jan; 12(1):195-200. van 't Veer LJ, Beijersbergen RL, Bernards R. PMID: 8428579.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    56. Structure and expression of major histocompatibility complex-binding protein 2, a 275-kDa zinc finger protein that binds to an enhancer of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1992 Oct 01; 89(19):8971-5. van 't Veer LJ, Lutz PM, Isselbacher KJ, Bernards R. PMID: 1409593.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    57. Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression? Semin Cancer Biol. 1991 Feb; 2(1):73-83. Schrier PI, Versteeg R, Peltenburg LT, Plomp AC, van 't Veer LJ, Krüse-Wolters KM. PMID: 1912519.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    58. Two genes encode factors with NF-kappa B- and H2TF1-like DNA-binding properties. Proc Natl Acad Sci U S A. 1990 Nov; 87(22):8707-10. Rustgi AK, Van 't Veer LJ, Bernards R. PMID: 2247438.
      View in: PubMed   Mentions: 17     Fields:    Translation:Cells
    59. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol. 1989 Jul; 9(7):3114-6. van 't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, Schrier PI, Bos JL. PMID: 2674680.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    60. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res. 1988 Jun 15; 48(12):3355-9. Kuppen PJ, Schuitemaker H, van 't Veer LJ, de Bruijn EA, van Oosterom AT, Schrier PI. PMID: 2897238.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    61. ras oncogene activation in human ovarian carcinoma. Oncogene. 1988 Feb; 2(2):157-65. van 't Veer LJ, Hermens R, van den Berg-Bakker LA, Cheng NC, Fleuren GJ, Bos JL, Cleton FJ, Schrier PI. PMID: 3285294.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    62. High frequency of mas oncogene activation detected in the NIH3T3 tumorigenicity assay. Oncogene Res. 1988; 3(3):247-54. van 't Veer LJ, van den Berg-Bakker LA, Hermens RP, Deprez RL, Schrier PI. PMID: 3060802.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    63. Molecular cloning and chromosomal assignment of the human homolog of int-1, a mouse gene implicated in mammary tumorigenesis. Mol Cell Biol. 1984 Nov; 4(11):2532-4. van 't Veer LJ, van Kessel AG, van Heerikhuizen H, van Ooyen A, Nusse R. PMID: 6513929.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    Laura's Networks
    Concepts (391)
    Derived automatically from this person's publications.
    _
    Co-Authors (23)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _